Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Brueckl, WM; Herbst, L; Lechler, A; Fuchs, F; Schoeberl, A; Zirlik, S; Klein, P; Brunner, TB; Papadopoulos, T; Hohenberger, W; Hahn, EG; Wiest, GH.
Predictive and prognostic factors in small cell lung carcinoma (SCLC) - Analysis from routine clinical practice
ANTICANCER RES. 2006; 26(6C): 4825-4832.
Web of Science
PubMed
- Co-authors Med Uni Graz
- Brunner Thomas Baptist
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- Background: Prognostic and predictive factors of routine clinical practice among patients with small cell lung carcinoma (SCLC) were evaluated. Patients and Methods: Data from 106 patients with SCLC treated by first-line adriamycin, cyclophosphamide and etoposide (ACE) chemotherapy were analyzed. Multivariate analysis was performed. Results: The median overall survival (mOS) of patients was 9.36 months with mOS of 31%, 8% and 3% after 1, 2 and 5 years, respectively. Using multivariate analysis ECOG performance status (p = 0.008) and white blood count (WBC) (p = 0.022) were independent prognostic factors for mOS. With both, three groups of outcome (good, intermediate, poor) resulting in mOS of 15.8 months, 687 months and 3.35 months (p < 0.0001) could be established, respectively. The absence of brain metastases (p=0.002), dose reduction (p=0.002) and LDH value (p=0.017) were independent predictive markers. Additionally, female gender was predictive (p=0.025) for complete response (CR). Conclusion: Patients with a poor prediction profil might not benefit from ACE chemotherapy. As a consequence, prognostic/predictive factors should be included as stratification criteria in prospective clinical studies.
- Find related publications in this database (Keywords)
- small cell lung cancer (SCLC)
- prognostic factor
- response prediction